2016
DOI: 10.12737/23745
|View full text |Cite
|
Sign up to set email alerts
|

Anti-Angiogenic Therapy in Patients With Pathologic Myopia and Choroidal Neovascularization

Abstract: Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV).22patients (22eyes) with myopic CNV were included in the study. Mean age was 54.0±14.4years, axial length – 28.25±1.9mm, follow-up – from 12 to 59months (mean follow-up – 26.9±13.8months). Ranibizumab was administered intravitreally according to the label in patients with active CNV confirmed by fluorescein angiography. The treatment was shown to have favorable early a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 3 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?